경제성평가자료제출생략 트랙으로 진입한 약제에 대한 외국의 치료적 이익 평가 결과 비교 (Comparative Review of Added Health Benefits of the Drugs Listed through Economic Evaluation Exemption Procedure in Korea: Cases of France, Germany, and Canada)

서지정보

· 발행기관 : 대한약학회
· 수록지 정보 : 약 학 회 지 / 68권 / 1호 / 62 ~ 70페이지
· 저자명 : 배은영, 차소희, 임화령, 이혜재, 홍지형

초록

This study assessed the additional health benefits of the drugs listed through the Economic EvaluationExemption Procedure (EEEP) in Korea. We conducted a comparative review of 32 EEEP drugs listed between May 2015and July 2022, comparing how they were assessed in France, Germany, and Canada. To collect the data, we reviewed theevaluations conducted by the relevant agency in each country and identified if the additional benefit exists and howsignificant it is. Additionally, the size of the benefit gains assessed by each agency was categorized as "High" or "Low,"allowing us to evaluate the consistency among these countries. In France, only 38% of the 34 drugs compareddemonstrated moderate or higher levels of additional benefit. Germany acknowledged substantial benefit improvement in27% of the 30 drugs assessed, while 73% showed minor, unquantifiable, or no additional benefits. In Canada, 5 out of22 cases have been identified as providing significant additional benefit. The level of inter-country consistency in theassessment results from these three countries was somewhat limited. Based on the evaluation results in France, Germany,and Canada, the additional benefits of EEEP drugs over existing treatments were not substantial in many cases. Eventhough the EEEP was introduced to improve accessibility to high-cost drugs for medical conditions with unmet needs, itis necessary to reconsider whether to allow exceptions for drugs with low therapeutic value.

영어초록

This study assessed the additional health benefits of the drugs listed through the Economic EvaluationExemption Procedure (EEEP) in Korea. We conducted a comparative review of 32 EEEP drugs listed between May 2015and July 2022, comparing how they were assessed in France, Germany, and Canada. To collect the data, we reviewed theevaluations conducted by the relevant agency in each country and identified if the additional benefit exists and howsignificant it is. Additionally, the size of the benefit gains assessed by each agency was categorized as "High" or "Low,"allowing us to evaluate the consistency among these countries. In France, only 38% of the 34 drugs compareddemonstrated moderate or higher levels of additional benefit. Germany acknowledged substantial benefit improvement in27% of the 30 drugs assessed, while 73% showed minor, unquantifiable, or no additional benefits. In Canada, 5 out of22 cases have been identified as providing significant additional benefit. The level of inter-country consistency in theassessment results from these three countries was somewhat limited. Based on the evaluation results in France, Germany,and Canada, the additional benefits of EEEP drugs over existing treatments were not substantial in many cases. Eventhough the EEEP was introduced to improve accessibility to high-cost drugs for medical conditions with unmet needs, itis necessary to reconsider whether to allow exceptions for drugs with low therapeutic value.

참고자료

· 없음